Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Clint Salo

Psychiatry Irvine, CA Doctor of Osteopathy

NPI 1811159221 CMS profile 127807

17782 Cowan, Suite A, Irvine, CA 92614

Open in the dashboard

General payments

$4,505

147 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Clint Salo of Irvine, CA is reported in the CMS Open Payments database as having received $4,505 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,072 31
2024 General $618 22
2023 General $854 19
2022 General $751 22
2021 General $428 15
2020 General $192 10
2019 General $591 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clint Salo
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Clint Salo were reported at $1,072. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Clint Salo Psychiatry median Middle half National median
2019 $591 $184 $59–$605 $163
2020 $192 $119 $36–$372 $114
2021 $428 $143 $43–$576 $132
2022 $751 $153 $50–$590 $149
2023 $854 $170 $56–$651 $160
2024 $618 $179 $57–$673 $164
2025 $1,072 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $1,216 24 payments
  2. Janssen Pharmaceuticals, Inc $877 35 payments
  3. Alkermes, Inc. $824 31 payments
  4. E.R. Squibb & Sons, L.L.C. $604 16 payments
  5. Indivior Inc. $297 11 payments
  6. ACADIA Pharmaceuticals Inc $189 5 payments
  7. Otsuka America Pharmaceutical, Inc. $149 7 payments
  8. Teva Pharmaceuticals USA, Inc. $133 6 payments
  9. AbbVie, Inc. $70 3 payments
  10. ITI, Inc. $34 2 payments
  11. Other $113 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,483 146 payments
  2. Travel and Lodging $23 1 payment
Products named General payments · program years 2019–2025
  1. INGREZZA $1,197 23 payments
  2. INVEGA SUSTENNA $825 33 payments
  3. ARISTADA Cns $796 30 payments
  4. ARISTADA Cns $796 30 payments
  5. INVEGA TRINZA $760 30 payments
  6. ARISTADA Cns $657 24 payments
  7. ARISTADA Cns $657 24 payments
  8. ARISTADA INITIO $584 22 payments
  9. COBENFY $402 11 payments
  10. LYBALVI $379 15 payments
  11. Other $1,623 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

5,745

Median for Psychiatry: 574

Drug cost

$2,240,180

Median for Psychiatry: $27,624

Branded share of claims

21.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 242 $767,157
Ingrezza Valbenazine Tosylate Brand 101 $680,285
Abilify Maintena Aripiprazole Brand 63 $161,065
Austedo Deutetrabenazine Brand 33 $140,274
Invega Trinza Paliperidone Palmitate Brand 14 $112,396
Austedo Xr Deutetrabenazine Brand 16 $81,852
Lurasidone Hcl Generic 110 $49,111
Fanapt Iloperidone Brand 11 $44,202
Rexulti Brexpiprazole Brand 27 $40,427
Vraylar Cariprazine Hcl Brand 25 $37,418

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$4,399

Medicare's payments for the services billed

Medicare patients

16

Average age 54

Services billed

68

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PERSERIS
  • Indivior Inc. $146
$146 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $57
$57 101 —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $50
$50 — —
ARISTADA
  • Alkermes, Inc. $41
$41 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record